From the Department of Orthopaedic Surgery, University of Louisville School of Medicine and the Kenton D. Leatherman Spine Center, Louisville, Kentucky.
Acknowledgment date: May 10, 2004. First revision date: July 20, 2004. Acceptance date: August 23, 2004.
Supported by a research grant from Norton Healthcare. Drs. Steven D. Glassman, John R. Dimar, John R. Johnson, Mitchell J. Campbell, and Rolando M. Puno are consultants and receive royalties and research grant support from Medtronic Sofamor Danek.
The device(s)/drug(s) that is/are the subject of this manuscript is/are being evaluated as part of an ongoing FDA-approved investigational protocol (IDE) or corresponding national protocol for IDE G00137: A prospective, randomized clinical investigation of recombinant human bone morphogenetic protein-2 and compression resistant matrix with the CD-horizon spinal system for posterolateral fusion in patients with symptomatic degenerative disc disease.
Corporate/Industry and Foundation funds were received to support this work. One or more of the author(s) has/have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this manuscript: e.g., honoraria, gifts, consultancies, royalties, stocks, stock options, decision making position.
Address correspondence and requests for reprints to Steven D. Glassman, MD, 210 East Gray Street, Suite 900, Louisville, KY 40202; E-mail: [email protected]
